6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Originaltext

Diese Übersetzung bewerten

Mit deinem Feedback können wir Google Übersetzer weiter verbessern

Latest Press Releases

Time	Headline
2h ago	STAR DIAMOND CORPORATION ANNOUNCES FIRST QUARTER 2026 RESULTS
2h ago	Hestia Capital Management Distributes 1.5 Million Shares of Pitney Bowes to Limited Partners
2h ago	Brookfield Asset Management Announces Results of Annual Meeting of Shareholders
2h ago	argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
2h ago	SINOVAC Reports Unaudited First Half of 2025 Financial Results

About

Immuneonco Biopharmaceuticals (shanghai) Inc Class H — investor relations, events, news, and company updates on 6ix.

Latest News

Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

Community Chat

Ask AI